Development of a real-world evidence platform in NF2 to examine treatment patterns and outcomes

Neurofibromatosis type 2 (NF2) is a rare disease, and its low prevalence can make it challenging to conduct clinical research on long-term clinical outcomes of patients who use off-label therapies for management. See how AllStripes’ real-world data (RWD) platform can be used to understand disease burden and treatment patterns over time. This poster was presented at Children’s Tumor Foundation’s Neurofibromatosis Virtual Conference in June 2020.